25 XP   0   0   10

Chemomab Therapeutics Ltd DRC
Buy, Hold or Sell?

Let's analyse Chemomab together

PenkeI guess you are interested in Chemomab Therapeutics Ltd DRC. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Chemomab Therapeutics Ltd DRC. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Chemomab Therapeutics Ltd DRC

I send you an email if I find something interesting about Chemomab Therapeutics Ltd DRC.

Quick analysis of Chemomab (30 sec.)










What can you expect buying and holding a share of Chemomab? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
6.3%

What is your share worth?

Current worth
$1.25
Expected worth in 1 year
$-0.16
How sure are you?
25.0%

+ What do you gain per year?

Total Gains per Share
$-1.41
Return On Investment
-239.2%

For what price can you sell your share?

Current Price per Share
$0.59
Expected price per share
$0.551 - $0.807
How sure are you?
50%

1. Valuation of Chemomab (5 min.)




Live pricePrice per Share (EOD)

$0.59

Intrinsic Value Per Share

$-18.47 - $-21.65

Total Value Per Share

$-17.22 - $-20.40

2. Growth of Chemomab (5 min.)




Is Chemomab growing?

Current yearPrevious yearGrowGrow %
How rich?$16.9m$47.4m-$26.2m-123.5%

How much money is Chemomab making?

Current yearPrevious yearGrowGrow %
Making money-$6m-$6.9m$909.5k15.0%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Chemomab (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#612 / 1019

Most Revenue
#990 / 1019

Most Profit
#456 / 1019

Most Efficient
#430 / 1019

What can you expect buying and holding a share of Chemomab? (5 min.)

Welcome investor! Chemomab's management wants to use your money to grow the business. In return you get a share of Chemomab.

What can you expect buying and holding a share of Chemomab?

First you should know what it really means to hold a share of Chemomab. And how you can make/lose money.

Speculation

The Price per Share of Chemomab is $0.59. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Chemomab.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Chemomab, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $1.25. Based on the TTM, the Book Value Change Per Share is $-0.35 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.46 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Chemomab.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.25-43.0%-0.44-75.4%-0.51-86.0%-0.30-51.4%-0.30-51.4%
Usd Book Value Change Per Share-0.08-13.0%-0.35-59.8%-0.46-78.5%0.0813.2%0.0813.2%
Usd Dividend Per Share0.000.0%0.000.0%0.023.7%0.010.9%0.010.9%
Usd Total Gains Per Share-0.08-13.0%-0.35-59.8%-0.44-74.8%0.0814.1%0.0814.1%
Usd Price Per Share0.51-1.08-3.55-5.58-5.58-
Price to Earnings Ratio-0.50--0.61--1.90--7.12--7.12-
Price-to-Total Gains Ratio-6.64--3.84--8.89--6.92--6.92-
Price to Book Ratio0.41-0.67-1.02-1.86-1.86-
Price-to-Total Gains Ratio-6.64--3.84--8.89--6.92--6.92-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.59
Number of shares1694
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.01
Usd Book Value Change Per Share-0.350.08
Usd Total Gains Per Share-0.350.08
Gains per Quarter (1694 shares)-597.69141.41
Gains per Year (1694 shares)-2,390.76565.66
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-2391-240137528556
20-4782-47927510571122
30-7172-718311215851688
40-9563-957414921142254
50-11954-1196518626422820
60-14345-1435622431703386
70-16735-1674726136993952
80-19126-1913829842274518
90-21517-2152933547565084
100-23908-2392037352845650

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%1.015.00.06.3%1.015.00.06.3%1.015.00.06.3%
Book Value Change Per Share0.04.00.00.0%2.010.00.016.7%4.012.00.025.0%4.012.00.025.0%4.012.00.025.0%
Dividend per Share0.00.04.00.0%1.00.011.08.3%1.00.015.06.3%1.00.015.06.3%1.00.015.06.3%
Total Gains per Share0.04.00.00.0%2.010.00.016.7%4.012.00.025.0%4.012.00.025.0%4.012.00.025.0%

Fundamentals of Chemomab

About Chemomab Therapeutics Ltd DRC

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.

Fundamental data was last updated by Penke on 2024-04-11 04:31:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Chemomab Therapeutics Ltd DRC.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Chemomab earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Chemomab to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Chemomab Therapeutics Ltd DRC:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--197.2%+197.2%
TTM--210.4%+210.4%
YOY--279.3%+279.3%
5Y--436.8%+436.8%
10Y--599.3%+599.3%
1.1.2. Return on Assets

Shows how efficient Chemomab is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Chemomab to the Biotechnology industry mean.
  • -15.6% Return on Assets means that Chemomab generated $-0.16 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Chemomab Therapeutics Ltd DRC:

  • The MRQ is -15.6%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -21.4%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-15.6%TTM-21.4%+5.8%
TTM-21.4%YOY-13.8%-7.6%
TTM-21.4%5Y-13.3%-8.1%
5Y-13.3%10Y-13.3%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-15.6%-13.6%-2.0%
TTM-21.4%-12.9%-8.5%
YOY-13.8%-11.9%-1.9%
5Y-13.3%-14.2%+0.9%
10Y-13.3%-16.2%+2.9%
1.1.3. Return on Equity

Shows how efficient Chemomab is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Chemomab to the Biotechnology industry mean.
  • -20.3% Return on Equity means Chemomab generated $-0.20 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Chemomab Therapeutics Ltd DRC:

  • The MRQ is -20.3%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -27.6%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-20.3%TTM-27.6%+7.3%
TTM-27.6%YOY-15.6%-12.0%
TTM-27.6%5Y-16.3%-11.3%
5Y-16.3%10Y-16.3%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-20.3%-17.0%-3.3%
TTM-27.6%-16.1%-11.5%
YOY-15.6%-15.4%-0.2%
5Y-16.3%-20.0%+3.7%
10Y-16.3%-21.1%+4.8%

1.2. Operating Efficiency of Chemomab Therapeutics Ltd DRC.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Chemomab is operating .

  • Measures how much profit Chemomab makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Chemomab to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Chemomab Therapeutics Ltd DRC:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--286.1%+286.1%
TTM--224.4%+224.4%
YOY--288.4%+288.4%
5Y--475.2%+475.2%
10Y--624.7%+624.7%
1.2.2. Operating Ratio

Measures how efficient Chemomab is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Chemomab Therapeutics Ltd DRC:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.997-2.997
TTM-3.247-3.247
YOY-3.766-3.766
5Y-5.675-5.675
10Y-7.857-7.857

1.3. Liquidity of Chemomab Therapeutics Ltd DRC.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Chemomab is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 4.32 means the company has $4.32 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Chemomab Therapeutics Ltd DRC:

  • The MRQ is 4.319. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.343. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ4.319TTM4.343-0.023
TTM4.343YOY11.108-6.765
TTM4.3435Y12.036-7.694
5Y12.03610Y12.0360.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.3193.930+0.389
TTM4.3434.251+0.092
YOY11.1085.436+5.672
5Y12.0366.045+5.991
10Y12.0366.363+5.673
1.3.2. Quick Ratio

Measures if Chemomab is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Chemomab to the Biotechnology industry mean.
  • A Quick Ratio of 6.49 means the company can pay off $6.49 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Chemomab Therapeutics Ltd DRC:

  • The MRQ is 6.488. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 6.469. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ6.488TTM6.469+0.019
TTM6.469YOY19.142-12.674
TTM6.4695Y17.238-10.770
5Y17.23810Y17.2380.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.4883.629+2.859
TTM6.4694.065+2.404
YOY19.1425.397+13.745
5Y17.2385.993+11.245
10Y17.2386.277+10.961

1.4. Solvency of Chemomab Therapeutics Ltd DRC.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Chemomab assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Chemomab to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.23 means that Chemomab assets are financed with 23.3% credit (debt) and the remaining percentage (100% - 23.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Chemomab Therapeutics Ltd DRC:

  • The MRQ is 0.233. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.225. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.233TTM0.225+0.007
TTM0.225YOY0.103+0.122
TTM0.2255Y0.148+0.077
5Y0.14810Y0.1480.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2330.332-0.099
TTM0.2250.334-0.109
YOY0.1030.268-0.165
5Y0.1480.366-0.218
10Y0.1480.390-0.242
1.4.2. Debt to Equity Ratio

Measures if Chemomab is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Chemomab to the Biotechnology industry mean.
  • A Debt to Equity ratio of 30.3% means that company has $0.30 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Chemomab Therapeutics Ltd DRC:

  • The MRQ is 0.303. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.291. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.303TTM0.291+0.012
TTM0.291YOY0.117+0.175
TTM0.2915Y0.186+0.106
5Y0.18610Y0.1860.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3030.381-0.078
TTM0.2910.390-0.099
YOY0.1170.334-0.217
5Y0.1860.434-0.248
10Y0.1860.466-0.280

2. Market Valuation of Chemomab Therapeutics Ltd DRC

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Chemomab generates.

  • Above 15 is considered overpriced but always compare Chemomab to the Biotechnology industry mean.
  • A PE ratio of -0.50 means the investor is paying $-0.50 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Chemomab Therapeutics Ltd DRC:

  • The EOD is -0.582. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.503. Based on the earnings, the company is expensive. -2
  • The TTM is -0.608. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.582MRQ-0.503-0.079
MRQ-0.503TTM-0.608+0.105
TTM-0.608YOY-1.901+1.293
TTM-0.6085Y-7.124+6.516
5Y-7.12410Y-7.1240.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.582-2.315+1.733
MRQ-0.503-2.560+2.057
TTM-0.608-2.664+2.056
YOY-1.901-4.122+2.221
5Y-7.124-6.258-0.866
10Y-7.124-6.108-1.016
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Chemomab Therapeutics Ltd DRC:

  • The EOD is -0.515. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.445. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.598. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.515MRQ-0.445-0.070
MRQ-0.445TTM-0.598+0.153
TTM-0.598YOY-2.527+1.929
TTM-0.5985Y-8.523+7.925
5Y-8.52310Y-8.5230.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.515-3.067+2.552
MRQ-0.445-3.251+2.806
TTM-0.598-3.545+2.947
YOY-2.527-5.595+3.068
5Y-8.523-8.315-0.208
10Y-8.523-8.708+0.185
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Chemomab is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.41 means the investor is paying $0.41 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Chemomab Therapeutics Ltd DRC:

  • The EOD is 0.473. Based on the equity, the company is cheap. +2
  • The MRQ is 0.409. Based on the equity, the company is cheap. +2
  • The TTM is 0.668. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.473MRQ0.409+0.064
MRQ0.409TTM0.668-0.260
TTM0.668YOY1.020-0.351
TTM0.6685Y1.861-1.193
5Y1.86110Y1.8610.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.4731.905-1.432
MRQ0.4092.111-1.702
TTM0.6682.095-1.427
YOY1.0202.836-1.816
5Y1.8613.443-1.582
10Y1.8613.794-1.933
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Chemomab Therapeutics Ltd DRC.

3.1. Institutions holding Chemomab Therapeutics Ltd DRC

Institutions are holding 24.989% of the shares of Chemomab Therapeutics Ltd DRC.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Advisory Services Network, LLC0.04470.00014786-6387-57.1646
Total 0.04470.00014786-6387-133.5%

3.2. Insider Transactions

Insiders are holding 16.624% of the shares of Chemomab Therapeutics Ltd DRC.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-01-03Israel Gp Ltd. OrbimedSELL3369003.58
2022-11-16George Adi MorSELL3247752.08
2022-11-16Neil Harris CohenSELL24092
2022-03-18Joel Michael MarylesBUY10004.34
2022-03-16Donald MarvinBUY5003.27
2022-03-14Dale R PfostBUY25003.98
2022-03-14Donald MarvinBUY12504.04
2022-03-14Neil Harris CohenBUY60004.35
2021-12-06Neil Harris CohenBUY20007.43

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Chemomab Therapeutics Ltd DRC compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.077-0.353+360%-0.463+504%0.078-198%0.078-198%
Book Value Per Share--1.2481.560-20%3.485-64%2.574-52%2.574-52%
Current Ratio--4.3194.343-1%11.108-61%12.036-64%12.036-64%
Debt To Asset Ratio--0.2330.225+3%0.103+126%0.148+57%0.148+57%
Debt To Equity Ratio--0.3030.291+4%0.117+160%0.186+63%0.186+63%
Dividend Per Share----0%0.022-100%0.005-100%0.005-100%
Eps---0.254-0.445+75%-0.507+100%-0.303+20%-0.303+20%
Free Cash Flow Per Share---0.286-0.435+52%-0.375+31%-0.285-1%-0.285-1%
Free Cash Flow To Equity Per Share---0.129-0.371+187%-0.389+201%0.030-533%0.030-533%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---21.646--------
Intrinsic Value_10Y_min---18.472--------
Intrinsic Value_1Y_max---1.504--------
Intrinsic Value_1Y_min---1.477--------
Intrinsic Value_3Y_max---5.025--------
Intrinsic Value_3Y_min---4.788--------
Intrinsic Value_5Y_max---9.158--------
Intrinsic Value_5Y_min---8.457--------
Market Cap8037393.000+14%6947577.00014678459.250-53%48326528.250-86%75977203.575-91%75977203.575-91%
Net Profit Margin----0%-0%-0%-0%
Operating Margin----0%-0%-0%-0%
Operating Ratio----0%-0%-0%-0%
Pb Ratio0.473+14%0.4090.668-39%1.020-60%1.861-78%1.861-78%
Pe Ratio-0.582-16%-0.503-0.608+21%-1.901+278%-7.124+1317%-7.124+1317%
Price Per Share0.590+14%0.5101.078-53%3.548-86%5.577-91%5.577-91%
Price To Free Cash Flow Ratio-0.515-16%-0.445-0.598+34%-2.527+468%-8.523+1815%-8.523+1815%
Price To Total Gains Ratio-7.687-16%-6.644-3.839-42%-8.887+34%-6.918+4%-6.918+4%
Quick Ratio--6.4886.469+0%19.142-66%17.238-62%17.238-62%
Return On Assets---0.156-0.214+37%-0.138-12%-0.133-15%-0.133-15%
Return On Equity---0.203-0.276+36%-0.156-23%-0.163-20%-0.163-20%
Total Gains Per Share---0.077-0.353+360%-0.441+475%0.083-192%0.083-192%
Usd Book Value--16997101.00021246206.250-20%47479750.000-64%35059676.563-52%35059676.563-52%
Usd Book Value Change Per Share---0.077-0.353+360%-0.463+504%0.078-198%0.078-198%
Usd Book Value Per Share--1.2481.560-20%3.485-64%2.574-52%2.574-52%
Usd Dividend Per Share----0%0.022-100%0.005-100%0.005-100%
Usd Eps---0.254-0.445+75%-0.507+100%-0.303+20%-0.303+20%
Usd Free Cash Flow---3902837.460-5926780.883+52%-5109500.000+31%-3877382.721-1%-3877382.721-1%
Usd Free Cash Flow Per Share---0.286-0.435+52%-0.375+31%-0.285-1%-0.285-1%
Usd Free Cash Flow To Equity Per Share---0.129-0.371+187%-0.389+201%0.030-533%0.030-533%
Usd Market Cap8037393.000+14%6947577.00014678459.250-53%48326528.250-86%75977203.575-91%75977203.575-91%
Usd Price Per Share0.590+14%0.5101.078-53%3.548-86%5.577-91%5.577-91%
Usd Profit---3454035.000-6061211.250+75%-6970750.000+102%-4409802.813+28%-4409802.813+28%
Usd Revenue----0%-0%-0%-0%
Usd Total Gains Per Share---0.077-0.353+360%-0.441+475%0.083-192%0.083-192%
 EOD+5 -3MRQTTM+17 -12YOY+15 -165Y+6 -2510Y+6 -25

4.2. Fundamental Score

Let's check the fundamental score of Chemomab Therapeutics Ltd DRC based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.582
Price to Book Ratio (EOD)Between0-10.473
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than16.488
Current Ratio (MRQ)Greater than14.319
Debt to Asset Ratio (MRQ)Less than10.233
Debt to Equity Ratio (MRQ)Less than10.303
Return on Equity (MRQ)Greater than0.15-0.203
Return on Assets (MRQ)Greater than0.05-0.156
Total5/10 (50.0%)

4.3. Technical Score

Let's check the technical score of Chemomab Therapeutics Ltd DRC based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5028.900
Ma 20Greater thanMa 500.759
Ma 50Greater thanMa 1000.722
Ma 100Greater thanMa 2000.624
OpenGreater thanClose0.694
Total3/5 (60.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets22,151
Total Liabilities5,154
Total Stockholder Equity16,997
 As reported
Total Liabilities 5,154
Total Stockholder Equity+ 16,997
Total Assets = 22,151

Assets

Total Assets22,151
Total Current Assets20,897
Long-term Assets1,254
Total Current Assets
Cash And Cash Equivalents 9,368
Short-term Investments 10,492
Net Receivables 1,037
Inventory -1,037
Other Current Assets 1,037
Total Current Assets  (as reported)20,897
Total Current Assets  (calculated)20,897
+/-0
Long-term Assets
Property Plant Equipment 695
Long-term Assets Other 559
Long-term Assets  (as reported)1,254
Long-term Assets  (calculated)1,254
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities4,838
Long-term Liabilities316
Total Stockholder Equity16,997
Total Current Liabilities
Short-term Debt 76
Accounts payable 516
Other Current Liabilities 4,246
Total Current Liabilities  (as reported)4,838
Total Current Liabilities  (calculated)4,838
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)316
Long-term Liabilities  (calculated)0
+/- 316
Total Stockholder Equity
Retained Earnings -88,679
Other Stockholders Equity 105,676
Total Stockholder Equity (as reported)16,997
Total Stockholder Equity (calculated)16,997
+/-0
Other
Cash and Short Term Investments 19,860
Common Stock Shares Outstanding 13,014
Liabilities and Stockholders Equity 22,151
Net Debt -8,976
Net Working Capital 16,059
Short Long Term Debt Total 392



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312018-12-312013-03-31
> Total Assets 
9,484
-14,744
19,755
15,183
10,016
7,689
12,476
60,123
70,518
67,440
64,353
60,956
56,378
50,219
43,063
35,013
28,849
23,418
22,151
22,15123,41828,84935,01343,06350,21956,37860,95664,35367,44070,51860,12312,4767,68910,01615,18319,755-14,7449,484
   > Total Current Assets 
9,157
-14,744
18,211
14,677
9,672
7,388
11,839
59,523
68,835
65,842
62,688
59,340
54,830
48,725
41,736
33,778
27,705
22,366
20,897
20,89722,36627,70533,77841,73648,72554,83059,34062,68865,84268,83559,52311,8397,3889,67214,67718,211-14,7449,157
       Cash And Cash Equivalents 
5,724
-14,744
17,575
14,009
8,824
6,768
11,674
58,180
45,396
37,744
14,686
13,827
9,883
10,741
13,519
20,765
10,382
9,228
9,368
9,3689,22810,38220,76513,51910,7419,88313,82714,68637,74445,39658,18011,6746,7688,82414,00917,575-14,7445,724
       Short-term Investments 
0
0
0
0
0
0
24
23
21,524
26,524
46,475
43,579
41,841
35,725
26,374
11,941
16,207
12,216
10,492
10,49212,21616,20711,94126,37435,72541,84143,57946,47526,52421,5242324000000
       Net Receivables 
0
0
408
0
0
0
74
320
1,915
1,574
1,527
1,934
3,106
2,259
459
995
1,042
922
1,037
1,0379221,0429954592,2593,1061,9341,5271,5741,9153207400040800
       Other Current Assets 
3,433
0
228
668
848
620
724
1,000
23,439
28,098
1,348
45,513
44,947
37,984
1,384
13,013
1
0
1,037
1,0370113,0131,38437,98444,94745,5131,34828,09823,4391,00072462084866822803,433
   > Long-term Assets 
327
0
1,544
506
344
301
637
600
1,683
1,598
1,665
1,616
1,548
1,494
1,327
1,235
1,144
1,052
1,254
1,2541,0521,1441,2351,3271,4941,5481,6161,6651,5981,6836006373013445061,5440327
       Property Plant Equipment 
153
0
1,357
460
293
249
580
545
635
593
702
667
650
641
594
545
498
449
695
6954494985455946416506677025936355455802492934601,3570153
       Long Term Investments 
0
0
0
0
0
0
0
4
0
0
0
0
0
0
0
0
0
0
0
0000000000040000000
       Long-term Assets Other 
174
0
187
46
51
52
53
51
1,048
1,005
963
949
821
776
733
690
646
603
559
5596036466907337768219499631,0051,04851535251461870174
> Total Liabilities 
6,193
0
4,846
3,623
1,859
2,338
1,674
4,959
2,479
1,928
2,887
3,720
4,542
5,595
6,840
7,059
6,858
5,375
5,154
5,1545,3756,8587,0596,8405,5954,5423,7202,8871,9282,4794,9591,6742,3381,8593,6234,84606,193
   > Total Current Liabilities 
4,889
0
4,121
3,471
1,751
2,275
1,316
4,631
2,159
1,630
2,650
3,517
4,394
5,477
6,749
6,997
6,825
5,370
4,838
4,8385,3706,8256,9976,7495,4774,3943,5172,6501,6302,1594,6311,3162,2751,7513,4714,12104,889
       Short-term Debt 
0
0
391
188
168
0
70
69
72
61
106
116
132
126
123
115
108
105
76
7610510811512312613211610661726970016818839100
       Accounts payable 
761
0
0
602
974
482
93
2,083
472
481
1,336
1,487
1,433
1,247
1,688
2,217
2,347
731
516
5167312,3472,2171,6881,2471,4331,4871,3364814722,0839348297460200761
       Other Current Liabilities 
4,128
0
3,730
2,869
777
1,793
-96
2,479
1,615
1,088
1,208
1,914
2,829
4,104
4,938
4,665
4,370
4,534
4,246
4,2464,5344,3704,6654,9384,1042,8291,9141,2081,0881,6152,479-961,7937772,8693,73004,128
   > Long-term Liabilities 
1,304
0
725
152
108
63
358
328
320
298
237
203
148
118
91
62
33
5
316
31653362911181482032372983203283586310815272501,304
> Total Stockholder Equity
3,291
0
14,909
11,560
8,157
5,351
10,802
55,164
68,039
65,512
61,466
57,236
51,836
44,624
36,223
27,954
21,991
18,043
16,997
16,99718,04321,99127,95436,22344,62451,83657,23661,46665,51268,03955,16410,8025,3518,15711,56014,90903,291
   Common Stock
922
0
0
0
0
119,375
0
0
0
0
0
0
0
0
0
-1,218
0
0
0
000-1,218000000000119,3750000922
   Retained Earnings -88,679-84,622-80,542-72,572-63,819-55,547-47,467-41,277-36,173-31,137-28,169-25,399-23,695-114,896-112,447-108,966-105,4310-112,754
   Capital Surplus 0000000000000000000
   Treasury Stock0000000000000000000
   Other Stockholders Equity 
115,123
0
120,340
120,526
120,604
120,247
34,497
80,563
96,208
96,649
97,639
98,513
99,303
100,171
100,042
100,526
102,533
102,664
105,676
105,676102,664102,533100,526100,042100,17199,30398,51397,63996,64996,20880,56334,497120,247120,604120,526120,3400115,123



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-67
Gross Profit-67-67
 
Operating Income (+$)
Gross Profit-67
Operating Expense-25,327
Operating Income-25,393-25,393
 
Operating Expense (+$)
Research Development18,267
Selling General Administrative7,078
Selling And Marketing Expenses0
Operating Expense25,32725,345
 
Net Interest Income (+$)
Interest Income0
Interest Expense-0
Other Finance Cost-1,238
Net Interest Income1,238
 
Pretax Income (+$)
Operating Income-25,393
Net Interest Income1,238
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-24,159-26,628
EBIT - interestExpense = -25,393
-24,159
-24,159
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-25,393-24,159
Earnings Before Interest and Taxes (EBITDA)-25,327
 
After tax Income (+$)
Income Before Tax-24,159
Tax Provision-0
Net Income From Continuing Ops-24,221-24,159
Net Income-24,159
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses25,393
Total Other Income/Expenses Net1,235-1,238
 

Technical Analysis of Chemomab
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Chemomab. The general trend of Chemomab is BEARISH with 42.9% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Chemomab's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-42.9%) Bearish trend (42.9%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Chemomab Therapeutics Ltd DRC.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 0.6203 < 0.698 < 0.807.

The bearish price targets are: 0.633 > 0.63 > 0.551.

Tweet this
Chemomab Therapeutics Ltd DRC Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Chemomab Therapeutics Ltd DRC. The current mas is .

The long score for the Moving Averages is 4/14.
The longshort score for the Moving Averages is -6/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Chemomab Therapeutics Ltd DRC Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Chemomab Therapeutics Ltd DRC. The current macd is -0.01229211.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Chemomab price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Chemomab. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Chemomab price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Chemomab Therapeutics Ltd DRC Daily Moving Average Convergence/Divergence (MACD) ChartChemomab Therapeutics Ltd DRC Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Chemomab Therapeutics Ltd DRC. The current adx is 25.36.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -4/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Chemomab shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bearish trend. The ADX is trending up, so the bearish trend is strengthening.
Chemomab Therapeutics Ltd DRC Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Chemomab Therapeutics Ltd DRC. The current sar is 0.797204.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Chemomab Therapeutics Ltd DRC Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Chemomab Therapeutics Ltd DRC. The current rsi is 28.90. The current phase is Oversold in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 0/(-13 +13).

  • Oversold in bear market: Short-term excessive selling, potential for relief rally. Be cautious, consider taking short-term long positions. +1
  • Trending down: The RSI is trending down. -1
Chemomab Therapeutics Ltd DRC Daily Relative Strength Index (RSI) ChartChemomab Therapeutics Ltd DRC Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Chemomab Therapeutics Ltd DRC. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Chemomab price going down in the near term. -2
  • Trending up: The STOCH %K is trending up. +1
Chemomab Therapeutics Ltd DRC Daily Stochastic Oscillator ChartChemomab Therapeutics Ltd DRC Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Chemomab Therapeutics Ltd DRC. The current cci is -329.79865264.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Chemomab Therapeutics Ltd DRC Daily Commodity Channel Index (CCI) ChartChemomab Therapeutics Ltd DRC Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Chemomab Therapeutics Ltd DRC. The current cmo is -61.21994354.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Chemomab Therapeutics Ltd DRC Daily Chande Momentum Oscillator (CMO) ChartChemomab Therapeutics Ltd DRC Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Chemomab Therapeutics Ltd DRC. The current willr is -95.1754386.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Chemomab Therapeutics Ltd DRC Daily Williams %R ChartChemomab Therapeutics Ltd DRC Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Chemomab Therapeutics Ltd DRC.

Chemomab Therapeutics Ltd DRC Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Chemomab Therapeutics Ltd DRC. The current atr is 0.05354752.

Chemomab Therapeutics Ltd DRC Daily Average True Range (ATR) ChartChemomab Therapeutics Ltd DRC Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Chemomab Therapeutics Ltd DRC. The current obv is 78,120,691.

Chemomab Therapeutics Ltd DRC Daily On-Balance Volume (OBV) ChartChemomab Therapeutics Ltd DRC Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Chemomab Therapeutics Ltd DRC. The current mfi is 37.57.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Chemomab Therapeutics Ltd DRC Daily Money Flow Index (MFI) ChartChemomab Therapeutics Ltd DRC Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Chemomab Therapeutics Ltd DRC.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-24DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-11-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-30STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-07MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-12-11STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-20CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-22WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-26STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-27CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-29STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-03CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-05CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-10MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-11CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-19CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-22WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-23MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-25DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-29DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-30MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-02CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-05STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-08WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-12STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-14STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-21WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-26RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-02-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-05CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-08RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-12MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-13RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-14WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-22SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-25CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-02CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-03STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-05WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-09SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-11CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-16SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-17ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).

6.3. Candlestick Patterns

Chemomab Therapeutics Ltd DRC Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Chemomab Therapeutics Ltd DRC based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5028.900
Ma 20Greater thanMa 500.759
Ma 50Greater thanMa 1000.722
Ma 100Greater thanMa 2000.624
OpenGreater thanClose0.694
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Chemomab with someone you think should read this too:
  • Are you bullish or bearish on Chemomab? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Chemomab? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Chemomab Therapeutics Ltd DRC

I send you an email if I find something interesting about Chemomab Therapeutics Ltd DRC.


Comments

How you think about this?

Leave a comment

Stay informed about Chemomab Therapeutics Ltd DRC.

Receive notifications about Chemomab Therapeutics Ltd DRC in your mailbox!